Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. It is recommended for patients who are symptomatic from metastatic disease to the brain that a starting dose of 4 to 8 mg/d of dexamethasone be considered. Brain metastases patients with moderate to severe symptoms related to mass effect Level 3: Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. If patients exhibit severe symptoms consistent with increased intracranial pressure, it is recommended that higher doses such as 16 mg/d or more be considered.
S
teroids have been used to assist in controlling peritumoral intracerebral edema in the care of patients with newly diagnosed metastatic brain disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Dexamethasone has been the most commonly used steroid due to its minimal mineralocorticoid effect. Steroids have been used for palliative care, and, in combination with surgery and radiation, to reduce treatmentrelated toxicity. This updated systematic review addresses the role of corticosteroids in the treatment of metastatic brain disease.
METHODS
The PubMed online database was searched for the period of October 1, 2008 through December 31, 2015, using the following queries in all fields: steroids and brain metastases, and dexamethasone and brain metastases. This inclusive search strategy was designed to capture all manuscripts pertaining to brain metastases and steroids for manual review and to determine if any more recent articles had been missed in the prior update. The reference lists of the most relevant and most recent articles were also reviewed, and additional articles were selected for initial review. Citations and references then screened using predetermined inclusion and exclusion criteria. Those meeting criteria were then retrieved for full-text review and assessment of bias. Those that were informative were chosen for evidence table creation, classified, and used for creation of recommendations as per the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) methods (https://www.cns.org/guidelines/guideline -procedures-policies/guideline-development-methodology).
RESULTS
The searches yielded 155 manuscripts over the abovementioned interval. Thirty two were chosen for full-text screening. However, after careful application of inclusion and exclusion criteria no new studies were eligible for creation of an evidence table or creation of new recommendations.
Two studies were included in the original 2010 guideline. 11 Vecht et al 13 reported both in one manuscript and first conducted a randomized study of 4, 8, and 16 mg/d dosing of dexamethasone and demonstrated no advantage to higher dosing in patients without symptomatic intracranial hypertension. Two consecutive double-blind randomized trials in patients with brain metastases and Karnofsky Performance Status (KPS) of 80 or less were designed to evaluate the minimum effective dose of oral dexamethasone. Initially, a dexamethasone dosage of 8 mg/d (group 1) was compared to 16 mg/d (group 2), followed by a comparison of 4 mg/d (group 3) versus 16 mg/d (group 4). The outcomes of interest were alteration in KPS and the frequency of side effects at days 0, 7, 28, and 56. Both groups showed improvement, but there was no significant difference in KPS improvement comparing the 8-mg group versus the 16-mg group at day 7 (mean 8.0 ± 10.1 vs 7.3 ± 14.2).
In the second trial, also by Vecht et al 13 both groups showed improvement. There was no significant difference between the 4-mg and 16-mg groups, comparing 6.7 ± 11.3 points at day 7 and 7.1 ± 18.2 points at day 28 vs 9.1 ± 12.4 and 5.6 ± 18.5 points, respectively. Side effects were more frequent in the 16 mg/d versus the 4-mg/day group at day 28 (combined frequency 91% vs 46%, P < .03). The authors concluded that the lower doses of 4 and 8 mg dexamethasone per day had an equivalent effect on improving neurological performance when compared to a dose of 16 mg/d at 1 and 4 wk of treatment, in moderately symptomatic patients without signs of impending herniation. The dosing recommendation from this study was 4 mg/d dosage with a dose taper for 28 d in patients with no symptoms of mass effect.
The publications that report the Quality of Life after Treatment for Brain Metastases (QUARTZ) trial 1, 8, 12, 14 were summarized in the publication by Mulvenna et al in 2016. 1, 12 This series of articles compares palliative whole brain radiotherapy versus supportive care with steroids, and is significant in that they appear to establish the role of steroids as a baseline of care for the symptomatic patient with central nervous system metastasis. They provide randomized data on the comparison of whole brain radiotherapy versus steroids alone but also provide no comparative data on dosing or the comparison of no steroid versus steroid. The Mulvenna study was published after the literature review for this guideline was performed, but is referenced for completeness, even though it was not included as evidence to support the recommendations of this guideline update. It appears that this issue has been assumed to be adequately addressed with clinical practice, as no comparative studies addressing this issue have appeared in over 20 y.
DISCUSSION
Although comparative studies addressing various steroid dosing regimens are generally lacking, studies addressing additional topics of interest have been published in recent years. 1, 2, 5, 6, 12 A better understanding of the toxicity related to routine steroid use continues to develop, and this research would support the principle of using the lowest effective steroid dose. 6, 15 The design of large clinical trials in which a steroid treatment-only group is considered the "best supportive care" group underlines the conviction most physicians hold for the critical role of steroids in managing the patient with symptomatic central nervous system metastatic disease. 1, 8, 14 The issue of dosing regimen is problematic to address based on the evidence available. The study noted by Vecht et al 13 used only 4 times daily dosing and does not address alternative dosing regimens. Therefore, only recommendations on total amount per day have been formulated. It is recognized as common practice that alternative dosing, such as twice daily is acceptable practice.
In addition, the ability of steroids to reduce the likelihood of treatment-related toxicity, either following surgery or radiotherapy, continues to be of interest and warrants additional study at least as a component of the data collection process in clinical trials. 3, 5 It is clear from this review of the literature that steroids are a mainstay of treatment for patients with metastatic brain disease despite the relative lack of high-quality evidence supporting any specific therapy. Based on the literature available for this guideline update, larger prospective or carefully planned retrospective E190 | VOLUME 84 | NUMBER 3 | MARCH 2019
www.neurosurgery-online.com studies should be considered in order to clarify more specific patient-dependent dosing. Complications related to steroid use, including adrenal insufficiency with tapering, should continue to be monitored, and perhaps alternative approaches to reducing peritumoral edema could be explored to eliminate the unwanted but common side effects of steroid therapy entirely. Additional information including updates, reviews, and consensus documents is available on this topic that is informative but does not meet the criteria for inclusion in an evidence-based document. This includes surveys on steroid doses and taper patterns commonly used: retrospective risk: benefit surveys, and retrospective analyses of the impact of preoperative steroids. Detailed discussion about each of the items is available in the full guideline, which can be accessed at https://www.cns.org/ guidelines/guidelines-treatment-adults-metastatic-brain-tumors/ chapter_7.
Disclosures
These evidence-based clinical practice guidelines were funded exclusively by the Congress of Neurological Surgeons and the Tumor Section of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons, which received no funding from outside commercial sources to support the development of this document.
Potential Conflicts of Interest
The Brain Metastases Guideline Update Task Force members were required to report all possible conflicts of interest (COIs) prior to beginning work on the guideline, using the COI disclosure form of the AANS/CNS Joint Guidelines Review Committee, including potential COIs that are unrelated to the topic of the guideline. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination. The CNS Guidelines Committee and Guideline Task Force Chair are given latitude to approve nominations of task force members with possible conflicts and address this by restricting the writing and reviewing privileges of that person to topics unrelated to the possible COIs. The authors of this paper have the following relationships to disclose: Dr Olson-American Cancer Society, Takeda, Arbor Pharmaceuticals; Dr Ryken-Medtronic Inc, EBM Care Inc, Arbor Pharmaceuticals LLC, K2M Spine Inc. The COI findings are provided in detail in the companion introduction and methods manuscript (https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-braintumors/chapter_1).
Disclaimer of Liability
This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
